| CASE REPORT |
|
| Ahead of Print |
|
|
Retinal vasoproliferative tumor regression after intravitreal aflibercept
Ting-Wen Chu1, Shawn H Tsai2, Lee-Jen Chen1
1 Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan
2 Department of Ophthalmology, Mackay Memorial Hospital; Department of Optometry, Mackay Junior College of Medicine, Nursing, and Management; Department of Medicine, Mackay Medical College, Taipei, Taiwan
Correspondence Address:
Shawn H Tsai,
Department of Ophthalmology, Mackay Memorial Hospital, No. 92, Section 2, Zhongshan N. Road, Taipei 10449
Taiwan
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/tjo.tjo_21_22
|
|
|
Retinal vasoproliferative tumors (RVPTs) are rare benign retinal lesions typically located in the inferotemporal peripheral retina. Several treatment options exist for the management of RVPTs, but no consensus has been proposed. There are only a few reports on the use of anti-vascular endothelial growth factor with bevacizumab to treat exudative or neovascular retinal changes secondary to RVPTs. This report describes a 68-year-old female with a history of systemic hypertension that presented with a 2-week history of gradual loss of visual acuity in the right eye. Fundoscopic examination showed a RVPTs with atypical location that had a favorable response to two-intravitreal aflibercept injections 1 month apart, with resulting subretinal fluid absorption and tumor regression.
|
|
|
|
|
|
|
Search Pubmed for